All-cause and cause-specific mortality assessment in patients receiving sodium glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials

By afschroeder • March 29, 2026

Jaiswal V, Mashkoor Y, Waqas M, Khan MS, Ahmed A, Deb N, Banach M, Dani SS, Zelniker TA, Alexander KM, Fonarow GC, Qamar A. All-cause and cause-specific mortality assessment in patients receiving sodium glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials. Am J Med. 2026 Mar 26:S0002-9343(26)00227-5. doi: 10.1016/j.amjmed.2026.03.024. Epub ahead of print. PMID: 41903643.

Tags: Cardiology/Epi, cardiovascular mortality, Chronic kidney disease, diabetes, heart failure, mortality, outcome analysis, Publications, SGLT2I

A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design

Wazni OM, Chun KJ, Amin A, Anic A, Ajijola OA, Gibson DN, Mansour M, Makati K, Chrispin J, Duytschaever M, Nair DG, Piccini JP, Natale[...]

Cardiac Myxoma With Atypical Presentation Leading to Delayed Diagnosis: A Case Report

Alishala M, Trinh T, Lee JS. Cardiac Myxoma With Atypical Presentation Leading to Delayed Diagnosis: A Case Report. Cureus. 2026 Feb 26;18(2):e104308. doi: 10.7759/cureus.104308. PMID:[...]

Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study

Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, Kang YM, Weinland J, Ran X, Murphy SA, Zhang S, Li D, Banach[...]